Pfizer Completes Acquisition of Baxter’s Marketed Vaccines

December 1, 2014 Pfizer Inc. today announced that it has completed the acquisition of Baxter International Inc.’s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. As previously announced, Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured. “NeisVac-C and FSME-IMMUN/Ticovac are a strong fit with our vaccines …